Our study defines the USP22-FoxM-integrin b1 axis as a previously unappreciated pathway in breast cancer initiation and metastasis, that can be therapeutically targeted to antagonize invasive breast cancers. This evidence concerns the gene USP22 and invasive breast carcinoma.